Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
FEV1/FVC ratio (post-bronchodilator) ≤70%
FEV1 (post-bronchodilator) ≤50% of predicted
Current smoker or ex-smoker
Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline
Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit B0 or a willingness to have a chest x-ray performed before baseline
You may not be if
COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline
Lower respiratory tract infection not resolved 4 weeks prior to baseline
Diagnosis of asthma and/or other relevant lung disease
Known alpha-1-antitrypsin deficiency
Need for long-term oxygen therapy defined as ≥16 hours/day
Clareo Health | Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
